UG»·Çò

ÄúÏÖÔÚµÄλÖãº ÍøÕ¾Ê×Ò³>´ÙÏúÖÐÐÄ

×Ô»¥²¹AAV£¨scAAV£©¡ª¡ª¿ìËÙ¡¢¸ßЧ¡¢³¤Ê±±í´ïÔØÌå

2022-03-03 09:32

ÖØ×éÏÙÏà¹Ø²¡¶¾£¨ Recombinant adeno-associated virus, rAAV£©ÊÇÒ»ÖÖÎÞ°üĤ¡¢ÒÔµ¥Á´DNAΪÒÅ´«ÎïÖÊ¡¢»ùÒò×éÈÝÁ¿4.7kbµÄ¸´ÖÆÈ±ÏÝÐÍϸС²¡¶¾¡£¡£rAAV¾ßÓжàÖÖѪÇåÐÍ¿ÉÇ×ÊȲî±ð°ÐÆ÷¹Ù£¬£¬£¬£¬£¬£¬ÃâÒßÔ­ÐÔ¼«µÍÇå¾²ÐԸߣ¬£¬£¬£¬£¬£¬2-3Öܿɵִï±í´ïá¯ÁëÇÒ³¤Ê±¼äÎȹ̱í´ïµÈÌØµã£¬£¬£¬£¬£¬£¬Òò´Ë£¬£¬£¬£¬£¬£¬rAAVÆÕ±éÓ¦ÓÃÓÚ¶¯ÎïÑо¿¡¢»ù´¡Ñо¿ºÍ»ùÒòÖÎÁÆÁìÓò¡£¡£
UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾

×Ô»¥²¹AAV£¨Self-complementary AAV, scAAV£©ÔÚrAAVµÄ»ù´¡ÉϽ«Æä±àÂëÇøÓòÉè¼Æ³ÉË«Á´DNA£¬£¬£¬£¬£¬£¬Òò´ËscAAVѬȾϸ°ûºó»¥²¹²¿·Ö»¥²¹ÐγÉË«Á´DNA£¬£¬£¬£¬£¬£¬È»ºó¾ÙÐÐת¼¡¢·­Ò룬£¬£¬£¬£¬£¬²»ÐèÆÚ´ýµÚ¶þÁ´DNAºÏ³É£¬£¬£¬£¬£¬£¬×÷·ÏÁËrAAV»ùÒò±í´ïµÄÏÞËÙ°ì·¨£¬£¬£¬£¬£¬£¬Ëõ¶ÌÁË×îÏȱí´ïµÄʱ¼ä£¬£¬£¬£¬£¬£¬scAAVѬȾºóÒ»Ñùƽ³£3-5Ìì¼´¿ÉµÖ´ï±í´ïá¯Áë¡£¡£µ«Ò²ÕýÊÇscAAVµÄË«Á´DNA½á¹¹£¬£¬£¬£¬£¬£¬ÖÂʹÆäÈÝÁ¿ËõСÖÁ2.1kb£¬£¬£¬£¬£¬£¬Òò±ðµÄÔ´Ä¿µÄ»ùÒò¾ÞϸÐèÒª¿ØÖÆÔÚ1kb×óÓÒ¡£¡£
UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
ͼ1 ssAAVÓëscAAV¸ÎÔà±í´ï£¨1E+11 VG/Ö»£¬£¬£¬£¬£¬£¬Î²¾²Âö×¢É䣩



×Ô»¥²¹AAVÓ¦ÓÃÁìÓò



1. ×ÌÈŰеãɸѡ

¶Ì·¢¼ÐRNA£¨Short hairpin RNA, shRNA£©¿Ë¡½ø²¡¶¾ÔØÌåѬȾϸ°ûºó£¬£¬£¬£¬£¬£¬ÔÚϸ°ûÖбí´ïС×ÌÈÅRNA£¨Small interfering RNA, siRNA£©£¬£¬£¬£¬£¬£¬ÒÖÖÆmRNAת¼£¬£¬£¬£¬£¬£¬ÊµÏÖÒÖÖÆÄ¿µÄ»ùÒò±í´ïÄ¿µÄ¡£¡£¹ØÓÚδ֪µÄ×ÌÈŰлùÒòµÄɸѡһÑùƽ³£½ÓÄÉÌåÍâʵÑéµÄ·½·¨¾ÙÐÐÑéÖ¤£¬£¬£¬£¬£¬£¬ÔÚϸ°ûϵÉϾÙÐÐÑé֤ʱ³£»£»áÓöµ½ÌåÍâÓÐÓùûÌåÄÚÎÞЧ¹ûµÄÇéÐΣ»£»»òÔÚÔ­´úϸ°ûÉÏÑéÖ¤£¬£¬£¬£¬£¬£¬Ô­´úϸ°ûÊèÉ¢ÄѶȴó¡¢×÷ÓýÄѶȸßҲͬÑùÖÆÔ¼ÁËshRNAµÄ°Ð»ùÒòЧ¹ûÑéÖ¤£»£»Í¨ÀýÌåÄÚɸѡ°ÐµãµÄ·½·¨ÓÖ´ó´óµÄÓ°ÏìÁËÑо¿µÄËÙÂÊ¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬scAAV-shRNAɸѡ×ÌÈŰеã¿ÉÒÔ¿ìËÙ²¢ÇÒ׼ȷµØ»ñµÃ×ÌÈÅЧ¹û£¬£¬£¬£¬£¬£¬¼«´óµÄ¼ÓËÙÁËÑо¿µÄЧÂÊ¡£¡£
UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾

2. »ùÒò±à¼­

CRISPR/Cas9ÊÖÒÕͨ¹ý¶Ô»ùÒòˮƽ²Ù×÷ʵÏÖ»ùÒòÇóý»ò»ùÒò¶¨µã±à¼­¡£¡£Ê¹Óò¡¶¾ÔØÌå±í´ïÏòµ¼RNA£¨guide RNA, gRNA£©£¬£¬£¬£¬£¬£¬ÅäºÏCas9СÊó/²¡¶¾£¬£¬£¬£¬£¬£¬¿ÉÒÔ¶ÔСÊóµÄÄ¿µÄ»ùÒò¾ÙÐб༭¡£¡£
UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
ͼ3 ¼¡Èâ×¢ÉäAAV9»ùÒò±à¼­Ôª¼þת´ïµ½D52 DMDСÊó¸ÄÉÆÓªÑø²»Á¼ÂѰױí´ï
£¨Min Y L, et al., Molecular Therapy, 2020£©



3. »ùÒòÇýµ

Cre-LoxPÖØ×éøϵͳÒòÆäÌØÒìÐÔ×Ó£¬£¬£¬£¬£¬£¬ÆÕ±éÓ¦ÓÃÔÚ»ùÒòÇóý£¨Knock out£¬£¬£¬£¬£¬£¬KO£©»òÇÃÈ루Knock in£¬£¬£¬£¬£¬£¬KI£©Ñо¿ÖУ¬£¬£¬£¬£¬£¬ÏÖÔÚ³£ÓÃת»ùÒòСÊóÀ´ÊµÏÖ¡£¡£×ª»ùÒòСÊóÓÉÓÚ¹¹½¨ÖÜÆÚ³¤£¬£¬£¬£¬£¬£¬¼ÛÇ®¸ß£¬£¬£¬£¬£¬£¬·±Óýʱ¼ä¾Ã£¬£¬£¬£¬£¬£¬²¿·Ö»ùÒòÇóý»ò¹ý±í´ïÅßÌ¥ÖÂËÀµÈÔµ¹ÊÔ­ÓÉÖÆÔ¼ÁËÑо¿µÄ˳Ëì¾ÙÐУ¬£¬£¬£¬£¬£¬È»¶ø£¬£¬£¬£¬£¬£¬²¡¶¾ÔØÌå¿ÉÒÔսʤÒÔÉÏÑо¿ÖзºÆðµÄÎÊÌâ¡£¡£scAAV-creÅäºÏFloxСÊóʹÓ㬣¬£¬£¬£¬£¬¿ÉÔÚ³ÉÄê»òÓ×ÄêСÊóÉÏʵÏÖ¿ìËÙ»ùÒòÇýµ£¨Knock down, KD£©¡£¡£

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾

4. ÌØÒìÐÔ±ê¼Ç

ÁíÍ⣬£¬£¬£¬£¬£¬Ê¹ÓÃCreСÊó»òscAAV-CreÅäºÏscAAV-DIOʵÏÖÔ½·¢Ï¸Äå¡¢¿ìËÙµÄϸ°û±ê¼Ç¡£¡£

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
ͼ5 scAAV-FLEx-mRuby2Ó«¹âÂѰ×ÔÚHVC(X)ϸ°ûȺÖÐÏÞÖÆÐÔ±í´ï
£¨Sánchez-Valpuesta M, et al.,PNAS, 2019£©



5. ¹ý±í´ï

ʹÓÃscAAV¹ý±í´ïÄ¿µÄ»ùÒò¿ÉÒÔʵÏÖ¸ÄÄ¿µÄ»ùÒòÔÚÌåÄÚ¿ìËÙ±í´ïµÄÄ¿µÄ£¬£¬£¬£¬£¬£¬¿ÉÊÇÖµµÃ×¢ÖØµÄÊÇ£¬£¬£¬£¬£¬£¬ÓÉÓÚscAAVÈÝÁ¿ÓÐÏÞ£¬£¬£¬£¬£¬£¬ÎªÁ˰ü¹Ü³ö¶¾¼°Ñ¬È¾Ð§ÂÊ£¬£¬£¬£¬£¬£¬Ä¿µÄ»ùÒòÖ»¹ÜÑ¡Ôñ1kbÒÔÄÚ¡£¡£

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾
ͼ6 scAAV9-GFPѬȾƤ²ã£¬£¬£¬£¬£¬£¬ÈýÌìЧ¹û



С½á

scAAV¾ßÓжàÖÖѪÇåÐÍ¡¢¿ìËÙ±í´ï¡¢Îȹ̱í´ï¡¢ÃâÒßÔ­ÐÔÏà¶Ô½ÏµÍµÄÌØµã£¬£¬£¬£¬£¬£¬Òò´ËÊÊÓÃÓÚ¶àÖÖÓ¦Óó¡¾°¡£¡£

Copyright ? UG»·Çò    µØµã£ºÉϺ£ÊÐÆÖ¶«ÐÂÇø¹ú¼ÊÒ½Ñ§Ô°Çø×ÏÆ¼Â·908Ū19ºÅÂ¥

UG»·Çò¡¤(ÖйúÇø)¹Ù·½ÍøÕ¾

µã»÷ѯ¼Û

¡¾ÍøÕ¾µØÍ¼¡¿